Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026

Iovance reports 50% response rate in small pilot sarcoma trial, but data remain early.

What the company is saying

Iovance Biotherapeutics highlights a 50% objective response rate for lifileucel in a pilot trial of eight patients with metastatic UPS and DDLPS, describing the efficacy as 'unprecedented' and responses as 'deep' and 'durable.' The company emphasizes that all four partial responses are ongoing at 6+, 26+, 40+, and 46+ weeks, and that these patients had significant disease burden and were refractory to 1–7 prior systemic therapies. Executives Brian Gastman, M.D., and Lauren Banks, M.D., Ph.D., frame these results as setting a new bar for TIL therapy in refractory sarcoma and stress the lack of approved immunotherapy options for this population. Iovance notes the FDA granted fast track designation for lifileucel in advanced UPS and DDLPS in Q2 2026, based on these initial results. The company is now rapidly enrolling the SARATOGA registrational Phase 2 trial at MSKCC and other major U.S. cancer centers, aiming to support two new approvals. The announcement positions Iovance as a global leader in TIL therapy, referencing its first-in-class FDA approval for Amtagvi in advanced melanoma and its commercial reach at nearly 100 authorized treatment centers.

What the data suggests

The pilot trial enrolled eight evaluable patients with metastatic UPS or DDLPS, all refractory to 1–7 prior systemic therapies and with baseline tumor diameters ranging from 39.0 to 177.6 mm. The confirmed objective response rate by RECIST v1.1 was 50%, with four partial responses—two in each sarcoma subtype—ongoing at 6+, 26+, 40+, and 46+ weeks as of September 9, 2026. No complete responses or deaths are reported. The safety profile is said to be consistent with prior lifileucel experience, but no quantitative safety data are disclosed. The incidence of soft tissue sarcomas is low, at 4–5 cases per 100,000 annually in Europe and 3.5 per 100,000 in the U.S., with metastatic UPS and DDLPS patients typically facing a median overall survival under two years and median progression-free survival of 5–6 months after first-line chemotherapy. Current second-line therapies yield less than 5% ORR, mPFS of 2–3 months, and mOS of 9–10 months, according to cited studies. The SARATOGA Phase 2 trial (NCT07741877) is enrolling, with ORR by independent review as the primary endpoint. No financial data, enrollment numbers, or timelines for regulatory submission are provided. The evidence is limited by the very small sample size and absence of a control arm.

Analysis

The announcement presents positive pilot trial results for lifileucel in rare soft tissue sarcomas, with a 50% ORR among eight evaluable patients and ongoing partial responses. These are realised, specific clinical outcomes, but the sample size is very small and the results are preliminary. The tone is highly positive, using phrases like 'unprecedented efficacy' and 'deep, durable responses' without direct comparative data or statistical context. The main forward-looking claim is the ongoing SARATOGA Phase 2 trial, which is still enrolling and intended to support future approvals—these benefits are long-term and not imminent. No financial, revenue, or profitability data are disclosed, and there is no mention of capital outlay or immediate commercial impact. The gap between narrative and evidence lies in the extrapolation from a small, early-stage dataset to broad claims of efficacy and future adoption.

Risk flags

• ●The pilot trial's efficacy data are based on only eight evaluable patients, which is too small to draw robust or generalizable conclusions about lifileucel's effectiveness in UPS and DDLPS. Small sample sizes are prone to statistical variability and may not reflect outcomes in broader populations.
• ●No quantitative safety data are disclosed for this cohort, making it impossible to independently assess the risk profile of lifileucel in these sarcoma subtypes. Safety signals could emerge in larger or more diverse patient groups.
• ●The SARATOGA Phase 2 trial is still enrolling, with no disclosed enrollment rate or timeline for completion, creating uncertainty about when pivotal data will be available and whether the observed efficacy will be replicated.
• ●The company makes strong qualitative claims ('unprecedented efficacy', 'deep, durable responses') that are not directly supported by comparative statistical benchmarks or a control arm, increasing the risk that future results may not match early expectations.
• ●No financial, revenue, or commercial adoption data are provided, so the near-term impact on Iovance's business remains unclear and investors cannot assess the economic significance of this program at this stage.

Bottom line

Iovance's report of a 50% objective response rate for lifileucel in a pilot trial of eight heavily pre-treated sarcoma patients is a promising early signal, especially given the poor outcomes with current therapies. The FDA's fast track designation for UPS and DDLPS reflects the high unmet need and initial promise, but the dataset is very small, lacks a control group, and does not include quantitative safety outcomes. The SARATOGA Phase 2 trial is still enrolling, and no timeline for data readout or regulatory submission is provided, so any commercial or clinical impact is likely months or years away. The company's narrative is confident and positions lifileucel as a potential new standard, but investors should recognize the high execution risk and the possibility that larger trials may yield less dramatic results. The most important takeaway is that while the pilot data are encouraging, the investment case hinges on the forthcoming SARATOGA trial results and subsequent regulatory milestones. Investors should watch for enrollment updates, interim data, and any disclosures on safety or commercial planning.

Announcement summary

(NASDAQ: IOVA) Iovance Biotherapeutics, Inc. announced that one-time lifileucel monotherapy demonstrated unprecedented efficacy with deep, durable responses in two difficult-to-treat soft tissue sarcomas, metastatic undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS), in a pilot trial presented at the ESMO Congress 2026 in Madrid, Spain. Among the first eight evaluable patients, the physician-assessed confirmed objective response rate (ORR) by RECIST v1.1 was 50%. Four partial responses (2 in UPS and 2 in DDLPS) were all ongoing at 6+, 26+, 40+, and 46+ weeks as of the data cut-off on September 9, 2026. The eight evaluable patients had deep responses despite significant disease burden, with baseline target sum of diameters ranging from 39.0 to 177.6 mm, were refractory to prior lines of systemic therapy (range: 1-7), and received lifileucel that met pre-determined manufacturing specifications. The safety profile was consistent with the lifileucel treatment regimen across other indications. Soft tissue sarcomas comprise approximately 80 tumor subtypes, with an estimated incidence of 4–5 cases per 100,000 people annually in Europe and approximately 3.5 new diagnoses per 100,000 people in the United States each year. Patients with metastatic UPS and DDLPS have a median overall survival (mOS) of less than two years and median progression-free survival (mPFS) of only 5 to 6 months after first-line chemotherapy. In recent clinical studies, current second-line treatment options delivered an ORR of less than 5%, mPFS of approximately 2-3 months, and mOS of approximately 9-10 months. The U.S. Food and Drug Administration (FDA) granted fast track designation for lifileucel in advanced UPS and DDLPS in the second quarter of 2026 based on initial results from the pilot trial. Iovance is rapidly enrolling the SARATOGA (NCT07741877) registrational Phase 2 clinical trial to support two new approvals for lifileucel, with the trial now enrolling at Memorial Sloan Kettering Cancer Center (MSKCC) and other major U.S. cancer centers. The primary endpoint of SARATOGA is ORR per RECIST v1.1 by independent review committee, with secondary endpoints including complete response rate, duration of response, disease control rate, progression-free survival, overall survival, and safety and tolerability. Iovance is also exploring lifileucel in additional metastatic soft tissue sarcomas with high unmet need as part of its clinical development program. Amtagvi (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at nearly 100 authorized treatment centers. The Iovance TIL platform includes registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. The ESMO Congress 2026 takes place October 23–27, 2026, at IFEMA Madrid, Spain, and features presentations of practice-changing clinical data, translational science, and educational programming across all major tumor types. The ESMO Congress brings together more than 37,000 clinicians, researchers, patient advocates, and industry representatives from around the world.

Disagree with this article?